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Abstract 
Bladder cancer (BC) has a typical aetiology characterized by a multistep carcinogenesis due to 
environmental exposures, genetic susceptibility and their interaction. Several lines of evidence suggest 
that DNA repair plays a role in the development and progression of BC. In particular, the study of 
individual susceptibility to DNA double strand breaks (DSBs) may provide valuable information on BC 
risk, and help to identify those patients at high-risk of either recurrence or progression of the disease, 
possibly personalizing both surveillance and treatment. 
Among the different DSB markers, the most well-characterized is phosphorylation of the histone H2AX 
(γ-H2AX). We assessed any potential role of γ-H2AX as a molecular biomarker in a case-control study 
(146 cases and 146 controls) to identify individuals with increased BC risk and at high-risk of disease 
recurrence or progression. We investigated γ-H2AX levels in peripheral blood mononuclear cells before 
and after their exposure to ionizing radiation (IR). We did not find any significant difference among cases 
and controls. However, we observed a significant association between γ-H2AX basal levels and risk of 
disease recurrence or progression. In particular, both BC patients as a whole and the subgroup of non-
muscle invasive BC (NMIBC) with high basal H2AX phosphorylation levels had a decreased risk of 
recurrence or progression (for all BC HR 0.70, 95% CI 0.52-0.94, p=0.02; for NMIBC HR 0.68, 95% CI 0.50-
0.92, p=0.01), suggesting a protective effect of basal DSB signalling. Our data suggest that γ-H2AX can be 
considered as a possible molecular biomarker to identify patients with a higher risk of BC recurrence.  
Summary 
We analysed γ-H2AX levels in peripheral blood mononuclear cells before and after exposure to ionizing 
radiation in a hospital-based study on bladder cancer. We observed that γ-H2AX basal levels were 
significantly associated with risk of disease recurrence or progression. 
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Introduction 
The maintenance of genome integrity is essential for human cells. The DNA damage response (DDR) 
pathway, which aims to restore the DNA to its original configuration, is a set of biochemical signalling 
and effector pathways that maintain genomic stability [1]. DNA double strand break (DSB) lesions, i.e. 
complete breaks of the DNA double helix, may impair DNA replication, transcription or distribution of the 
genetic material to daughter cells. DSBs are difficult to repair and since broken DNA ends tend to 
dissociate, unrelated ends may re-join thus allowing for gross loss or amplification of genomic 
information, as well as chromosomal rearrangements. All these kinds of damage are commonly 
associated with the early stages of cellular transformation and tumorigenesis [2]. 
Among the different DNA DSB markers, the most well-characterized is phosphorylation of the histone 
H2AX (γ-H2AX). Within minutes after the induction of a DSB, several thousands of H2AX molecules are 
phosphorylated at serine 139 near the site of damage with a crucial role in recruiting and maintaining 
many factors involved in DNA DSB repair [3]. Nonetheless, γ-H2AX is often used as a marker for exploring 
the spatial distribution and the DNA repair kinetics of cells following ionizing radiation (IR) exposure and 
it has also been suggested as a biomarker to predict patient response to specific radiotherapy 
treatments [4-8]. In the last years, γ-H2AX has become a widely used marker for DSB damage in 
translational studies, including areas such as carcinogenesis, radiation research, drug development and 
clinical assessment of DNA targeted anticancer therapies [8-10]. 
Bladder cancer (BC), which is the fourth most common malignancy among men in the Western world, 
has a typical aetiology characterized by a multistep carcinogenesis, reflecting that multiple lesions in the 
DNA are required for tumour development. More specifically, interaction between genetic susceptibility 
and environmental exposures is crucial. Among the latter, the most relevant risk factors associated with 
the occurrence of BC are tobacco smoking, occupational exposure to aromatic amines, IR and arsenic-
contaminated drinking water [11]. Exposure to these carcinogens causes different types of DNA damage, 
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including DSBs. For all these reasons, the identification of susceptibility to DSB may provide valuable 
information about individual cancer risk [12]. 
Non-muscle invasive BC (NMIBC) is characterized by a high risk of recurrence after endoscopic resection 
and intravesical therapy, especially within the first two years after diagnosis. Therefore, surveillance with 
repeated cystoscopies is mandatory to rule out recurrences. Several clinical and pathologic factors have 
been identified as predictors of tumour recurrence and progression, including stage, grade, size, 
multiplicity, presence of carcinoma in situ and previous recurrences [13]. However, given the limited 
accuracy of these traditional prognostic factors, the discovery of novel molecular biomarkers would be 
most useful in the early detection of patients at higher risk of recurrence. Such an improvement would 
allow a better sub classification of these patients, avoiding unnecessary cystoscopies in some cases while 
proceeding to more aggressive therapies in some others, with non-negligible health costs savings. The 
same goes for muscle-invasive BC (MIBC) patients, where the risk of disease recurrence after radical 
cystectomy remains relevant [14]. Several biomarkers, including chromosomal markers, genetic 
variations or epigenetic alterations, have been investigated in terms of recurrence prediction, but the 
results are still inconclusive [15,16]. 
In a relatively large ongoing hospital-based case-control study, H2AX phosphorylation has been 
evaluated as a potential molecular biomarker to identify individuals with increased BC risk or at higher 
risk of developing BC recurrence or progression. We investigated levels of H2AX phosphorylation before 
and after exposure to IR in peripheral blood mononuclear cells (PBMCs), the easiest cells to obtain for γ-
H2AX assessment in vivo. Our data highlight that γ-H2AX is not associated with BC risk as it does not 
differ among cases and controls. On the other hand, it can be considered as a possible molecular marker 
to identify patients with higher risk of BC recurrence, both in BC in general and NMIBC patients in 
particular. 
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Material and Methods 
Study population 
The study population included all newly diagnosed, histologically confirmed cases of BC registered at two 
urology departments of A.O. U. Città della Salute e della Scienza, formerly S. Giovanni Battista hospital, in 
Turin (Italy), during the years 1994–2008 [17]. All subjects were men, aged 40–75 years, living in the 
Turin metropolitan area and were enrolled for a large hospital-based study on BC: the Turin Bladder 
Cancer Study (TBCS) [11,18]. Before any treatment, a trained interviewer used a detailed questionnaire 
to conduct a face-to-face interview. Controls were men recruited daily in random fashion from patients 
treated at the same urology departments for non-neoplastic disease (prostatic hyperplasia, cystitis and 
others) or from patients treated at the medical and surgical departments for hernias, vasculopathies, 
diabetes, heart failure, asthma or other benign diseases. Patients with cancer, liver or renal diseases and 
smoking-related conditions were excluded [19]. Cases and controls were furtherly matched for age and 
smoking habit. All subjects were informed and provided written consent to participate in the study and 
to approve the use of their biological samples for the analyses, according to the Helsinki declaration. The 
design of the study was approved by the local Ethics Committee. Clinical information, including the type 
of therapy (e.g., Bacillus Calmette-Guerin (BCG), chemotherapy and radiotherapy), was recorded through 
the perusal of clinical records. Patients treated with one instillation of chemotherapy immediately after 
transurethral resection were not considered in the chemotherapy group. Patients with BC were followed 
by urologists with periodic cystoscopic examinations. Clinical end-points (progression and recurrence) 
were abstracted from clinical and pathology records by medical doctors with a standardized chart. 
Progression was defined as the transition from non-muscle invasive disease to invasive or metastatic 
disease, while recurrence was defined as a newly identified bladder tumour after a previous negative 
follow-up cystoscopy. Vital status was ascertained through linkage with the local demographic office and 
death certificates were retrieved to identify the specific causes of death. 
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Lymphocytes isolation and cryopreservation 
Ten ml of heparinized venous blood were collected from all subjects. PBMCs were separated by 
centrifugation with FicollPaque PLUS (GE Healthcare, Milan, Italy) at 400 x g for 30 minutes at room 
temperature. After two washes in RPMI 1640, 1% fetal bovine serum (FBS), 25 mM EDTA (all from Gibco, 
Life Technologies, Paisley, UK), PBMCs were prepared for cryopreservation. They were resuspended at 
10x106 cells/ml in freezing medium (RPMI 1640, 50% FBS, 10% DMSO), aliquoted in cryovials and slowly 
frozen overnight at the rate of –1°C/minute in isopropyl alcohol to –80°C (Mr. Frosty containers, 
Nalgene, Roskilde, Denmark). Cryovials were then transferred into liquid nitrogen for long-term storage. 
Case-control study 
Cryopreserved PBMCs from 146 cases (collected before treatment) and 146 controls matched by gender, 
age (±1 year) and smoking habits, were selected from the TBCS collection and employed for the 
phenotypic assay to evaluate H2AX phosphorylation. 
H2AX phosphorylation assay 
The assay was performed as previously described [20]. Briefly, PBMCs were thawed and allowed to 
recover overnight in RPMI 1640 (Gibco, Life Technologies) supplemented with 10% heat inactivated FBS 
(Sigma-Aldrich St Luis, MO, USA), 2mM L-Glutamine, 1% kanamycin, 1% sodium pyruvate, 1% 
nonessential amino acids, 0.1% β-mercaptoethanol (all from Gibco, Life Technologies). Cells were x-
irradiated (2 Gy) using 6 MV opposed beams with a linear accelerator Synergy Platform (Elekta, 
Stockholm, Sweden). They were kept on ice for 1 h, and then returned to the incubator and harvested at 
1 h and 3 h. Approximately 400,000 untreated and irradiated cells were collected, fixed in cold 70% 
ethanol and stored at −20 °C for up to 2 weeks before analysis. Cells were washed in Tris-buffered saline 
(TBS) pH 7.4 and then rehydrated for 10 min at 4 °C in TBS containing 4% FBS and 0.1% Triton X-100 (TST) 
(Sigma–Aldrich Co) prior to staining with anti-γH2AX mAb (clone JBW301, Millipore, Billerica, MA, USA) 
diluted at 1:250 in TST, and incubated for 2 h at 37 °C. After two washes in TBS, they were resuspended 
H2AX phosphorylation and survival in bladder cancer 
 7 
in PE-conjugated goat anti-mouse IgG1 (BD PharMingen, Becton Dickinson & Co., Franklin Lakes, NJ, USA) 
diluted at 1:100 in TST as a secondary antibody, and shaken for 1 h at room temperature in the dark. A 
minimum of 10,000 stained cells were acquired on a Cyan ADP flow cytometer (Beckman Coulter, Brea, 
CA, USA) and analysed with Summit 4.3 software. In order to normalize the results, aliquots of PBMCs 
derived from the same subject were used at each irradiation and staining step as reference control and 
flow cytometer setting relative to PE-fluorescence were established on the reference control untreated 
sample. Each experimental point was evaluated in technical triplicate. 
For the analysis, the mean of the reference control at each experimental point (untreated, 2 Gy 1 h and 2 
Gy 3 h) was calculated considering all the irradiation experiments. Raw data were subsequently 
normalized to the average signal of the reference control of each specific irradiation (Average 
normalization procedure). Data corresponding to the amount of γ-H2AX at 1 h were expressed as ratio of 
median γ-H2AX level at 1 h to the baseline γ-H2AX level of the same non-irradiated sample. Data 
corresponding to the dephosphorylation of γ-H2AX after 3 h of recovery were expressed for each sample 
as percentage of median γ-H2AX fluorescence of irradiated cells at 3 h on median γ-H2AX fluorescence at 
1 h. 
Statistical analyses 
The patient characteristics were described as absolute frequencies for qualitative variables, and median, 
minimum and maximum values for quantitative variables. The analysed variables were: basal damage in 
untreated cells, H2AX phosphorylation at 1 h (γ-H2AX ratio), and percentage of dephosphorylation after 
3 h. Eleven samples encountered technical problems during the assay performance, therefore they were 
excluded from further analysis together with their relative matched counterpart. Fisher exact test was 
used to ensure no under/over-representation of cases or death in the excluded samples. 
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For each of the considered variables we tested whether they were normally distributed by the Shapiro-
Wilk test. Since the variables were not normally distributed, non-parametric paired test (two-sided 
Wilcoxon Rank Sum test) was employed to verify differences between cases and controls. 
Overall Survival (OS) in patients was evaluated as the time from diagnosis using the date of death 
(regardless of the cause) or the date of follow up termination as the end point. Event-free survival (EFS) 
was defined as the time from diagnosis to the occurrence of any event such as recurrence, progression 
or death, whichever came first. Investigated variables were considered as continuous. The survival 
curves for OS and EFS were derived by the Kaplan–Meier (KM) method and statistical significance was 
determined using the log-rank test (R version 3.0.3, Survival package). The relative risk of death or of 
recurrence/progression was estimated as hazard ratio (HR) using Cox regression. Multivariate survival 
analyses were adjusted for matching variables, risk category (based on the six most significant clinical 
and pathological factors: number of tumours, tumour size, prior recurrence rate, T category, presence of 
concurrent CIS, and tumour grade (WHO1973) as described in [21,22]), and therapy for the whole group 
of patients. The investigated variables that resulted significantly associated with OS or EFS were also 
considered as categorical. Several cut-off values for the categorization of continuous variables were 
considered, and the one maximizing the area under the ROC curve (AUC) was chosen as the best cut-off. 
The study population was then divided according to the best cut-off into 2 groups: 1) the “Fast 
recognition of the damage” group, which included patients with the basal H2AX phosphorylation above 
the best cut-off value, and the “Slow recognition of the damage” group, which have the basal H2AX 
phosphorylation under the generated best cut-off value. 
To evaluate the improvement in the performance of EFS prediction when including the H2AX assay 
variables, discrimination analysis comparing two nested models was carried out: the first one included 
matching variables, risk category, and therapy; the second one included also H2AX assay variables. 
Discrimination analysis was conducted comparing the area under ROC curve (AUC) of the two nested 
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models by the De Long test [23]. All the analyses were performed with the open source R (version 3.0.3; 
survival package). 
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Results 
Study population 
The study included 146 males newly diagnosed, previously untreated BC patients and 146 control 
subjects, matched by age, gender and smoking habits. The epidemiological data, tumour histological 
classification and therapy details for the whole cohort are summarized in Table I. For 121 patients 
tumours were classified as NMIBC (Tis,Ta,T1), while 13 patients were MIBC (>T2). Thirty-one cases had 
grade G1 cancer, while 56 had G2 and 40 G3. Fifty cases were classified as high risk, 41 as intermediate 
and 30 as low risk. Most of the patients (69) were not treated with any therapy, whereas part of them 
were treated with chemotherapy (24 patients) and/or BCG (39 patients). 
During H2AX phosphorylation assay, technical problems were encountered for four controls and seven 
cases. Since no additional aliquots of cryopreserved PBMC were available, the experiments could not be 
repeated. Therefore, these samples were excluded from the analysis together with their relative 
matched samples. Finally, 135 matched couples were included in the case-control study and 139 cases 
were included in the overall and event-free survival analyses.  
Case-control study 
H2AX phosphorylation assay results are reported in Table II. We considered the basal H2AX 
phosphorylation as the basal individual level of DSB signalling, the H2AX phosphorylation after 1 h 
irradiation as the peak of DNA damage recognition and percentage of H2AX dephosphorylation after 3 h 
irradiation as the individual capacity to repair the induced damage. No significant differences were 
observed between cases and controls (Table II). Similarly, among all subgroups stratified for smoking 
habit, no significant differences were observed between cases and controls. There was only a significant 
difference in the percentage of H2AX dephosphorylation between cases and controls in smokers (p=0.05) 
(Supplementary Table I); however, these data refer a very small population (n=22) and for this reason 
the result has to be considered with caution. 
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Overall and event-free survival analyses 
Results from the survival analysis are reported in Table III. There was no association between overall 
survival in patients and γ-H2AX assay results. On the other hand, when analysing the EFS, there was a 
significantly decreased risk of recurrence/progression in patients with an increased basal H2AX 
phosphorylation level both for all BC patients and also when stratified only for NMIBC (HR 0.70, 95% CI 
0.52-0.94, p=0.02 and HR 0.68, 95% CI 0.50-0.92, p=0.01, respectively). 
We then repeated the analysis considering the significant variable as categorical (Table IV). Instead of 
separating samples according to the median value, we used the optimal cut-off value based on the AUC 
(see Methods). Two categories were generated: those individuals with the basal H2AX phosphorylation 
above the best cut-off value were included in the “Fast recognition of the damage” group, while those 
under the best cut-off value correspond to the “Slow recognition of the damage” group. A similar 
association between decreased risk of recurrence and basal H2AX phosphorylation above the calculated 
best cut-off was observed for all BC and NMIBC subjects: patients with high basal DSB signalling had a 
better EFS (HR 0.35, 95% CI 0.20-0.63, p=0.0005 and HR 0.32, 95% CI 0.17-0.62, p=0.0006, respectively).  
The results on EFS were confirmed also in the univariate KM analysis for the same model (log rank test p-
value=0.004 and 0.002, respectively for all BC and NMIBC, for the basal H2AX phosphorylation; Figure 1 
A, B). For EFS, the best cut-offs obtained to perform the analyses for the basal H2AX phosphorylation 
were 6.33 (considering all BC cases) and 6.29 (considering NMIBC cases). 
Finally, to evaluate the improvement in the prediction accuracy given by the H2AX assay, we assumed 2 
models, including respectively: i) matching variables (age and smoking habit), risk category and therapy 
as EFS predictors; ii) model i) plus H2AX assay variable resulted associated to EFS, i.e. basal damage in 
untreated cells. Comparing the AUC of the 2 models we found a statistically significant improvement in 
discrimination (AUC model 1 = 0.55; AUC model 2 = 0.63, DeLong's test p = 0.03). 
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Discussion 
DNA damage pathways have been shown to be implicated in BC risk [24]. To our knowledge there is a 
lack of studies evaluating the relationship between H2AX phosphorylation levels and the clinical 
outcome. In the present study we observed a significant association between H2AX basal 
phosphorylation level and BC recurrence risk. In particular, individuals with higher basal H2AX 
phosphorylation had a significantly decreased risk of recurrence, suggesting a protective effect of 
high basal DSB signalling in terms of preventing BC recurrences. One may speculate that individuals 
expressing high basal levels of γ-H2AX are capable of recruiting crucial DNA repair elements towards 
areas of DSBs and effectively activating the DNA repair pathway. Therefore, having a high basal H2AX 
phosphorylation implicates a constitutional activated response system in recognizing the damage, 
while those individuals having a low basal H2AX phosphorylation are in general slower in recognizing 
the basal damage. Interestingly, a study on H2AX phosphorylation in non-invasive low grade 
urothelial carcinoma (LG-URC) of the bladder demonstrated a significant higher recurrence rate in γ-
H2AX negative tumour tissues, suggesting a protective effect of γ-H2AX expression in terms of 
preventing LG-URC recurrences [25]. Surprisingly, we did not observe any association between the 1 
h H2AX phosphorylation peak and recurrence risk, although a borderline association was evidenced 
(for all BC HR 1.67, 95% CI 0.97-2.88, p=0.06; for NMIBC HR 1.79, 95% CI 0.88-3.67, p=0.11). One 
possible explanation for this partially missed observation could be that 2 Gy IR activates massive DSB 
signalling that might mask subtle individual differences. 
Additionally, considering the H2AX dephosphorylation capacity after 3 h from IR, individuals with 
higher dephosphorylation capacity had a decreased risk of recurrence, although not reaching a 
statistical significance. These findings suggest a protective effect of a rapid response in recognizing 
(basal H2AX phosphorylation) and repairing (3 h H2AX dephosphorylation) DNA damage, possibly 
preventing BC recurrence. 
Using the measured variables as categorical with a best cut-off analysis strategy, we obtained that 
the best cut-off to use were different from the median, allowing to hypothesize application of this 
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newly determined value on other BC populations and to propose the H2AX phosphorylation assay for 
clinical validation on a large scale. With this approach we obtained a similar result for basal DSB 
signalling and risk of recurrences. Moreover, in the present study a significant improvement in the 
sensitivity and specificity of EFS prediction can be achieved when considering basal cell damage as an 
independent risk factor, thus supporting the role of H2AX assay as a prognostic biomarker.  
Interestingly, we obtained analogous results restricting our analysis to NMIBC patients. These data 
are particularly relevant, considering that NMIBC is the most prevalent BC (75% of all BC) that recurs 
more frequently and often progresses to muscle-invasive bladder cancer, a deadly disease.  
As nearly half of patients with BC experiences recurrence, reliable predictors of this phenotype are 
needed to guide surveillance and treatment. The identification of γ-H2AX as a new molecular 
biomarker related to BC recurrence is particularly relevant. A risk assessment calculator that is based 
on several clinical-pathological parameters is available for NMIBC, but it has been reported to have 
potential flaws. In the last two decades, great effort has been made to evaluate the prognostic and 
predictive roles of several molecular markers in MIBC and, even more, in NMIBC, where a precise risk 
stratification is urgently needed. Several tissue- and blood-based biomarkers have been identified 
(reviewed in [15,26]). Although none of these biomarkers have reached the clinical validation level, 
for some of them (e.g., p53, pRb, p21, and survivin) the predictive value has been proved in studies 
that included a homogeneous patient population treated with standard therapy, and, therefore, they 
are probably ready for clinical validation on a larger scale and could help clinicians to provide 
individualized prognosis and allow risk-stratified clinical decision.  
DNA repair pathways may be also involved in the pathogenesis, progression, and treatment response 
of BC [27]. Many studies analysed predictive value of different DDR factors by immunohystochemical 
tissue analysis, but no data are available on molecular biomarkers in PBMCs to predict recurrence 
risk. Besides the previously described work that analysed H2AX phosphorylation in BC tissue [25], to 
the best of our knowledge there are no other studies investigating the role of γ-H2AX in the 
determination of BC survival and/or clinical outcome. The present study is the first one employing an 
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assay able to measure not only the peak of DNA damage recognition after irradiation, but also the 
individual capacity to recover and repair the induced damage. Another study analysed protein 
expression of MRE11, RAD50, NBS1, ATM, and H2AX by immunohistochemistry in pre-treatment 
bladder tumour specimens from three different cohorts to evaluate if predictive markers could be 
identified [28]. Authors demonstrated that patients with increased MRE11 expression levels had 
longer survival in comparison to patients with lower values. In other studies investigating DNA repair 
gene expression, decreased levels of hMSH2 and hMLH1 mismatch repair genes were associated with 
high grade bladder tumour recurrence [29]. It must be pointed out that previously published data 
regarding DNA damage factors related to BC referred mainly to immunohistochemical techniques on 
bladder tissues, while our results are based on the detection of a basal damage that could affect 
patient specific BC progression. The importance of patient’s basal genetic background and 
consequently of his damage repair capacity in predicting BC recurrence is highlighted by different 
studies where genetic variants in DNA repair genes that could modify BC prognosis were identified, 
including polymorphisms in XRCC1, XRCC4, XPF, XPD and XPC [30-33]. 
In BC, it is highly improbable that a single marker can accurately segregate tumours into precise 
prognostic categories. Therefore, as already shown by different investigators, combination of 
independent, complementary biomarkers may provide a more accurate prediction of outcome 
compared with any single markers [34,35]. Future investigations should focus on promising 
biomarker combinations that encompass a variety of different pathways to increase the predictive 
value and to improve their possible application for targeted therapy. H2AX phosphorylation could be 
proposed as another molecular biomarker to be evaluated in recurrence risk analysis.  
In the present study, there was no association between overall survival in patients and γ-H2AX assay 
results. This result may be due to the fact that in the population study only 24 patients deceased with 
a consequent not enough power to detect a prognostic effect. Moreover, we did not observe any 
differences between cases and controls using the H2AX phosphorylation assay. In contrast, other 
case-control studies reported differential γ-H2AX levels in PBMCs as a risk predictor for BC or other 
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neoplastic diseases, such us lung cancer and oesophageal adenocarcinoma, demonstrating higher IR-
induced γ-H2AX levels in cases than in control [36,37]. In particular, a study evaluating γ-H2AX levels 
on BC cases and controls found that a higher susceptibility to induction of DSBs was associated with 
an increased risk for BC [38]. This study presented a similar population study size (n=174 of which 
140 were males). However, the formation of γ-H2AX foci was assayed on lymphocytes subset in 
whole blood cultures. The discrepancy of our results with those observed in [38] could be attributed 
to the different cultures employed (whole blood and cryopreserved lymphocytes) or to inter and 
intra-individual differences in the relative abundance of the different subpopulations of lymphocytes 
(as observed by [39]).  
However, there are some important differences between previous studies and the present one. First, 
we used unstimulated PBMCs, whereas in previous studies 72 h PHA-stimulated PBMCs were 
employed. In this sense, the different results could be ascribed to the different responses in 
quiescent vs proliferating cells. Second, we detected γ-H2AX by flow cytometry, while in other works 
a laser scanning cytometer-based immunocytochemical method was used; these two techniques 
could have a different sensitivity. Finally, controls were recruited by us in a random fashion from 
patients treated at the same urology department for benign diseases, mainly prostate hyperplasia 
and cystitis (all newly diagnosed), or from patients treated at the medical and surgical departments 
for hernias, vasculopathies, diabetes, heart failure, asthma, or other benign diseases. In contrast, in 
previous studies most of the controls were enrolled during work annual health check-up. 
PBMCs have been used as a surrogate tissue in several studies evaluating DNA damage and can be 
considered as the current standard [39-41]. In addition to its simple collection from widely available 
blood samples, they provide favourable settings for basal DNA damage measurement before 
exposure to any mutagenic agent due to their quiescent nature, avoiding interference by DNA 
damage occurring during S-phase [38].  
There is a need to implement the identification of patients at risk for disease recurrence and/or 
progression. The current guidelines from the European Association of Urology (EAU) stated that 
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“more work is required to determine the role of molecular markers in improving the predictive 
accuracy of the currently existing risk tables” [22]. Notably, also in the present study the AUC model 
including several of the known epidemiology and clinical risk factors showed a quite limited overall 
prediction power. However, with the addition of the γ-H2AX biomarker, we observed an 
improvement in the prediction model. We are aware that the model is still limited since it is based on 
males only and the model presents still some limitations in the prediction power. However, it is 
important to note that the assay is based on a non-invasive methodology for the patients that could 
improve if applied on larger groups of patients. BC is almost three times more common in men than 
in women, therefore it is relatively “easier” to collect males patients. Performing the assay only on 
men reduced the variability. Moreover, it has been recently demonstrated that women with BC have 
poorer survival times than men. Some factors associated with a history of cystitis may contribute to 
or explain the poorer outcome, regardless of treatment and after adjustment for a range of other 
prognostic variables [42]. 
In conclusion, our data suggest that the H2AX phosphorylation assay applied on cryopreserved 
PBMCs can be considered as a possible useful molecular marker to identify BC patients with a higher 
risk of recurrence or progression, thus deserving clinical validation on a large scale. In small studies 
testing urine-based markers it has been shown a benefit in terms of survival for screened men with 
cost-effective consequences when implemented in high-risk populations, e.g. heavy smokers [43,44]. 
Our results support the inclusion of the DNA H2AX phosphorylation assay in future screening trials 
focused on high-risk cohorts in order to further assess its prognostic value in BC patients. 
 
 
Funding 
This work was supported by Fondazione Umberto Veronesi “Post-doctoral fellowship Year 2014 and 
2015” (Barbara Pardini recipient) and “Research Project Year 2013” (Giuseppe Matullo recipient) 
Acknowledgements 
H2AX phosphorylation and survival in bladder cancer 
 17 
The authors are very thankful to all patients that participated with enthusiasm to the present study 
and to the technical staff of the Radiation Oncology Unit, S. Luigi Hospital, Orbassano, Italy, for 
technical support in cell irradiation. 
Conflict of Interest Statement: None declared. 
 
References 
1. Kavanagh JN, Redmond KM, Schettino G, Prise KM. DNA double strand break repair: a 
radiation perspective. Antioxid Redox Signal 2013;18(18):2458-2472. 
2. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer 
connection. Nat Genet 2001;27(3):247-254. 
3. Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA 
double-strand breaks in the context of chromatin. Nucleic Acids Res 2008;36(17):5678-5694. 
4. Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human 
cells exposed to very low x-ray doses. Proc Natl Acad Sci U S A 2003;100(9):5057-5062. 
5. Costes SV, Chiolo I, Pluth JM, Barcellos-Hoff MH, Jakob B. Spatiotemporal characterization of 
ionizing radiation induced DNA damage foci and their relation to chromatin organization. 
Mutat Res 2010;704(1-3):78-87. 
6. Costes SV, Ponomarev A, Chen JL, Nguyen D, Cucinotta FA, Barcellos-Hoff MH. Image-based 
modeling reveals dynamic redistribution of DNA damage into nuclear sub-domains. PLoS 
Comput Biol 2007;3(8):e155. 
7. Schmid TE, Dollinger G, Beisker W et al. Differences in the kinetics of gamma-H2AX 
fluorescence decay after exposure to low and high LET radiation. Int J Radiat Biol 
2010;86(8):682-691. 
8. Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, Martin OA. Use of the gamma-H2AX assay 
to monitor DNA damage and repair in translational cancer research. Cancer Lett 2012;327(1-
2):123-133. 
9. Sedelnikova OA, Pilch DR, Redon C, Bonner WM. Histone H2AX in DNA damage and repair. 
Cancer Biol Ther 2003;2(3):233-235. 
10. Valdiglesias V, Giunta S, Fenech M, Neri M, Bonassi S. gammaH2AX as a marker of DNA 
double strand breaks and genomic instability in human population studies. Mutat Res 
2013;753(1):24-40. 
11. Burger M, Catto JW, Dalbagni G et al. Epidemiology and risk factors of urothelial bladder 
cancer. Eur Urol 2013;63(2):234-241. 
12. Bonner WM, Redon CE, Dickey JS et al. GammaH2AX and cancer. Nat Rev Cancer 
2008;8(12):957-967. 
13. Sylvester RJ, Brausi MA, Kirkels WJ et al. Long-term efficacy results of EORTC genito-urinary 
group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, 
bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with 
intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 
2010;57(5):766-773. 
14. Gakis G, Efstathiou J, Lerner SP et al. ICUD-EAU International Consultation on Bladder Cancer 
2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma 
of the bladder. Eur Urol 2013;63(1):45-57. 
H2AX phosphorylation and survival in bladder cancer 
 18 
15. Sanguedolce F, Bufo P, Carrieri G, Cormio L. Predictive markers in bladder cancer: Do we 
have molecular markers ready for clinical use? Crit Rev Clin Lab Sci 2014:1-14. 
16. van Rhijn BW, Catto JW, Goebell PJ et al. Molecular markers for urothelial bladder cancer 
prognosis: Toward implementation in clinical practice. Urol Oncol 2014. 
17. Matullo G, Guarrera S, Carturan S et al. DNA repair gene polymorphisms, bulky DNA adducts 
in white blood cells and bladder cancer in a case-control study. Int J Cancer 2001;92(4):562-
567. 
18. Sacerdote C, Guarrera S, Ricceri F et al. Polymorphisms in the XRCC1 gene modify survival of 
bladder cancer patients treated with chemotherapy. Int J Cancer 2013;133(8):2004-2009. 
19. Ricceri F, Guarrera S, Sacerdote C et al. ERCC1 haplotypes modify bladder cancer risk: a case-
control study. DNA Repair (Amst) 2010;9(2):191-200. 
20. Porcedda P, Turinetto V, Brusco A et al. A rapid flow cytometry test based on histone H2AX 
phosphorylation for the sensitive and specific diagnosis of ataxia telangiectasia. Cytometry A 
2008;73(6):508-516. 
21. Witjes JA, Comperat E, Cowan NC et al. EAU guidelines on muscle-invasive and metastatic 
bladder cancer: summary of the 2013 guidelines. Eur Urol 2014;65(4):778-792. 
22. Babjuk M, Burger M, Zigeuner R et al. EAU guidelines on non-muscle-invasive urothelial 
carcinoma of the bladder: update 2013. European urology 2013;64(4):639-653. 
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more 
correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 
1988;44(3):837-845. 
24. Wu X, Gu J, Grossman HB et al. Bladder cancer predisposition: a multigenic approach to DNA-
repair and cell-cycle-control genes. Am J Hum Genet 2006;78(3):464-479. 
25. Cheung WL, Albadine R, Chan T, Sharma R, Netto GJ. Phosphorylated H2AX in noninvasive 
low grade urothelial carcinoma of the bladder: correlation with tumor recurrence. J Urol 
2009;181(3):1387-1392. 
26. Xylinas E, Kluth LA, Lotan Y et al. Blood- and tissue-based biomarkers for prediction of 
outcomes in urothelial carcinoma of the bladder. Urol Oncol 2014;32(3):230-242. 
27. Chang DW, Gu J, Wu X. Germline prognostic markers for urinary bladder cancer: obstacles 
and opportunities. Urol Oncol 2012;30(4):524-532. 
28. Choudhury A, Nelson LD, Teo MT et al. MRE11 expression is predictive of cause-specific 
survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 
2010;70(18):7017-7026. 
29. Catto JW, Xinarianos G, Burton JL, Meuth M, Hamdy FC. Differential expression of hMLH1 
and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite 
instability. Int J Cancer 2003;105(4):484-490. 
30. Mittal RD, Singh R, Manchanda PK et al. XRCC1 codon 399 mutant allele: a risk factor for 
recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Cancer Biol 
Ther 2008;7(5):645-650. 
31. Andrew AS, Gui J, Hu T et al. Genetic polymorphisms modify bladder cancer recurrence and 
survival in a USA population-based prognostic study. BJU Int 2014. 
32. Wang M, Yuan L, Wu D et al. A novel XPF -357A>C polymorphism predicts risk and recurrence 
of bladder cancer. Oncogene 2010;29(13):1920-1928. 
33. Sanyal S, De Verdier PJ, Steineck G et al. Polymorphisms in XPD, XPC and the risk of death in 
patients with urinary bladder neoplasms. Acta Oncol 2007;46(1):31-41. 
34. Shariat SF, Karakiewicz PI, Ashfaq R et al. Multiple biomarkers improve prediction of bladder 
cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008;112(2):315-
325. 
35. Shariat SF, Chade DC, Karakiewicz PI et al. Combination of multiple molecular markers can 
improve prognostication in patients with locally advanced and lymph node positive bladder 
cancer. J Urol 2010;183(1):68-75. 
H2AX phosphorylation and survival in bladder cancer 
 19 
36. Xu E, Gong Y, Gu J, Jie L, Ajani JA, Wu X. Risk assessment of esophageal adenocarcinoma 
using gamma-H2AX assay. Cancer Epidemiol Biomarkers Prev 2013;22(10):1797-1804. 
37. He Y, Gong Y, Lin J et al. Ionizing radiation-induced gamma-H2AX activity in whole blood 
culture and the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2013;22(3):443-451. 
38. Fernandez MI, Gong Y, Ye Y et al. gamma-H2AX level in peripheral blood lymphocytes as a 
risk predictor for bladder cancer. Carcinogenesis 2013;34(11):2543-2547. 
39. Andrievski A, Wilkins RC. The response of gamma-H2AX in human lymphocytes and 
lymphocytes subsets measured in whole blood cultures. International journal of radiation 
biology 2009;85(4):369-376. 
40. Goutham HV, Mumbrekar KD, Vadhiraja BM et al. DNA double-strand break analysis by 
gamma-H2AX foci: a useful method for determining the overreactors to radiation-induced 
acute reactions among head-and-neck cancer patients. International journal of radiation 
oncology, biology, physics 2012;84(5):e607-612. 
41. Ismail IH, Wadhra TI, Hammarsten O. An optimized method for detecting gamma-H2AX in 
blood cells reveals a significant interindividual variation in the gamma-H2AX response among 
humans. Nucleic acids research 2007;35(5):e36. 
42. Tracey E, Watt H, Currow D, Young J, Armstrong B. Investigation of poorer bladder cancer 
survival in women in NSW, Australia: a data linkage study. BJU international 
2014;113(3):437-448. 
43. Messing EM, Madeb R, Young T et al. Long-term outcome of hematuria home screening for 
bladder cancer in men. Cancer 2006;107(9):2173-2179. 
44. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk 
population?: A cost per life-year saved analysis. Cancer 2006;107(5):982-990. 
 
Figure legend  
Fig. 1. Kaplan-Meier event-free survival (EFS) curves according to the basal H2AX phosphorylation for 
all bladder cancer patients (A) and for non-muscle invasive bladder cancer patients (B). Patients were 
stratified into 2 categories: those with the basal H2AX phosphorylation above the best cut-off value 
correspond to the “Fast recognition of the damage” group, those under the best cut-off value 
correspond to the “Slow recognition of the damage” group. MST, median survival time. 
 
